This article reviewed abemaciclib for the treatment of metastatic breast cancer. The authors provided updated clinical trial data for CDK4 and CDK6 inhibitors with a focus on abemaciclib, the most recently approved agent. It used this data to describe the drugs pharmacologic characteristics, administration schedules, efficacy in combination with endocrine agents, single-agent activity and tolerability profiles.
The latest review article published in Future Oncology discusses the use of abemaciclib for the treatment of metastatic breast cancer.
The addition of CDK4 and CDK6 inhibitors (abemaciclib, palbociclib or ribociclib) to endocrine therapy, as first-line treatment or following progression after initial endocrine therapy, significantly increased progression-free survival, objective response rates, and in some trials overall survival, compared with endocrine therapy alone in HR+/HER2- metastatic breast cancer. These CDK4 and CDK6 inhibitors are now approved in this context and have become a new standard of care. A hypothesis-generating exploratory analysis suggested that the addition of abemaciclib to endocrine therapy showed the largest effects in subgroups of women with indicators of poor prognosis, although these data require confirmation. This review provides updated clinical trial data for all three drugs in metastatic breast cancer, focusing on abemaciclib, the most recently approved agent.
Read the full article: